- Previous Close
12.69 - Open
12.44 - Bid 12.39 x 40000
- Ask 12.42 x 40000
- Day's Range
12.38 - 12.47 - 52 Week Range
12.22 - 19.69 - Volume
5,195 - Avg. Volume
212,650 - Market Cap (intraday)
14.129B - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
22.53 - EPS (TTM)
0.55 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield 0.12 (0.87%)
- Ex-Dividend Date Mar 27, 2024
- 1y Target Est
--
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others segments. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopy systems, surgical microscopes, endoscope reprocessors, and maintenance services. The Therapeutic Solutions Business segment provides urology, gynecology, respiratory, ear, nose, and throat products; GI endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials, such as synthetic bone filler, and orthopedic equipment. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Tokyo, Japan.
www.olympus-global.comRecent News: OLYMY
View MorePerformance Overview: OLYMY
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OLYMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OLYMY
View MoreValuation Measures
Market Cap
13.95B
Enterprise Value
13.96B
Trailing P/E
22.53
Forward P/E
19.57
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.18
Price/Book (mrq)
2.85
Enterprise Value/Revenue
2.12
Enterprise Value/EBITDA
11.44
Financial Highlights
Profitability and Income Statement
Profit Margin
8.43%
Return on Assets (ttm)
5.85%
Return on Equity (ttm)
12.99%
Revenue (ttm)
993.33B
Net Income Avi to Common (ttm)
96.43B
Diluted EPS (ttm)
0.55
Balance Sheet and Cash Flow
Total Cash (mrq)
220.26B
Total Debt/Equity (mrq)
31.76%
Levered Free Cash Flow (ttm)
113.59B